Clinical Trial Update: MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM [Phase 2]

View source ↗

Summary

The MMRC Horizon One adaptive platform trial evaluating therapies for relapsed or refractory multiple myeloma is in Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Multiple Myeloma Research Consortium | Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING